Cargando…
CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874688/ https://www.ncbi.nlm.nih.gov/pubmed/29518044 http://dx.doi.org/10.3390/biomedicines6010031 |
_version_ | 1783310210441412608 |
---|---|
author | Foster, Brittni M. Zaidi, Danish Young, Tyler R. Mobley, Mary E. Kerr, Bethany A. |
author_facet | Foster, Brittni M. Zaidi, Danish Young, Tyler R. Mobley, Mary E. Kerr, Bethany A. |
author_sort | Foster, Brittni M. |
collection | PubMed |
description | Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like cell or tumor progenitor cell, while recurrence at a secondary site is driven by metastatic cancer stem cells or metastasis-initiating cells. Ongoing efforts are aimed at identifying and characterizing these stem-like cells driving recurrence and metastasis. One potential marker for the cancer stem-like cell subpopulation is CD117/c-kit, a tyrosine kinase receptor associated with cancer progression and normal stem cell maintenance. Further, activation of CD117 by its ligand stem cell factor (SCF; kit ligand) in the progenitor cell niche stimulates several signaling pathways driving proliferation, survival, and migration. This review examines evidence that the SCF/CD117 signaling axis may contribute to the control of cancer progression through the regulation of stemness and resistance to tyrosine kinase inhibitors. |
format | Online Article Text |
id | pubmed-5874688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58746882018-03-29 CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance Foster, Brittni M. Zaidi, Danish Young, Tyler R. Mobley, Mary E. Kerr, Bethany A. Biomedicines Review Metastasis is the primary cause of cancer patient morbidity and mortality, but due to persisting gaps in our knowledge, it remains untreatable. Metastases often occur as patient tumors progress or recur after initial therapy. Tumor recurrence at the primary site may be driven by a cancer stem-like cell or tumor progenitor cell, while recurrence at a secondary site is driven by metastatic cancer stem cells or metastasis-initiating cells. Ongoing efforts are aimed at identifying and characterizing these stem-like cells driving recurrence and metastasis. One potential marker for the cancer stem-like cell subpopulation is CD117/c-kit, a tyrosine kinase receptor associated with cancer progression and normal stem cell maintenance. Further, activation of CD117 by its ligand stem cell factor (SCF; kit ligand) in the progenitor cell niche stimulates several signaling pathways driving proliferation, survival, and migration. This review examines evidence that the SCF/CD117 signaling axis may contribute to the control of cancer progression through the regulation of stemness and resistance to tyrosine kinase inhibitors. MDPI 2018-03-08 /pmc/articles/PMC5874688/ /pubmed/29518044 http://dx.doi.org/10.3390/biomedicines6010031 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Foster, Brittni M. Zaidi, Danish Young, Tyler R. Mobley, Mary E. Kerr, Bethany A. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title | CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title_full | CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title_fullStr | CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title_full_unstemmed | CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title_short | CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance |
title_sort | cd117/c-kit in cancer stem cell-mediated progression and therapeutic resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874688/ https://www.ncbi.nlm.nih.gov/pubmed/29518044 http://dx.doi.org/10.3390/biomedicines6010031 |
work_keys_str_mv | AT fosterbrittnim cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance AT zaididanish cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance AT youngtylerr cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance AT mobleymarye cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance AT kerrbethanya cd117ckitincancerstemcellmediatedprogressionandtherapeuticresistance |